Chronicling the COPD Patient Journey and change in COPD symptoms, quality of life and exacerbations following initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

Trial Identifier: D5980R00105
Sponsor: AstraZeneca
Collaborator:
Asthma Research Group Inc.
University Health Network
Start Date: September 2024
Primary Completion Date: March 2026
Study Completion Date: March 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario Windsor, Ontario, Canada, N8W 5V7